Azoulay D, Adam R, Castaing D, Savier E, Veilhan L A, Bismuth H
Centre Hépato-Biliaire, Hôpital Paul Brousse, France.
Chirurg. 2001 Jul;72(7):765-9. doi: 10.1007/s001040170103.
Hepatic resection is currently the only form of treatment that offers a chance of long-term survival, with rates ranging from 25% to 39%. However, a curative operation can be performed in only 10% of patients with colorectal metastases to the liver. Our policy is to increase the number of patients that can benefit from liver resection. Liver metastases can be considered as irresectable mainly in three different situations (sometimes associated): (I) large and/or poorly located tumors; (II) bilateral tumors in both liver lobes; (III) tumors technically resectable, but not operable because the liver remnant is too small, which is associated with a prohibitive risk of postoperative severe liver failure. The aim of this paper is to report the strategies we use in our center to achieve curative resection in these three schematic situations despite initial contraindications.
肝切除术是目前唯一能提供长期生存机会的治疗方式,长期生存率在25%至39%之间。然而,仅有10%的结直肠癌肝转移患者能够接受根治性手术。我们的策略是增加能够从肝切除术中获益的患者数量。肝转移瘤主要在三种不同情况下(有时相互关联)可被视为不可切除:(I)肿瘤体积大及/或位置不佳;(II)肝两叶均有双侧肿瘤;(III)肿瘤在技术上可切除,但由于剩余肝脏过小而无法手术,这与术后严重肝衰竭的高风险相关。本文旨在报告我们中心在这三种典型情况下尽管存在初始禁忌证仍实现根治性切除所采用的策略。